Related Experiment Videos
[Characteristic and effective usage of adriamycin]
1Dept. of Urology, Nippon Medical School.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 1, 1996
Summary
Adriamycin (doxorubicin) is a valuable anti-cancer antibiotic for treating bladder cancer. It is used intravesically for superficial tumors and in combination therapies for advanced stages, demonstrating broad utility in bladder cancer management.
Area of Science:
- Oncology
- Pharmacology
Context:
- Transitional cell carcinoma (TCC) of the bladder is a significant clinical challenge.
- Adriamycin (doxorubicin) is an established anti-cancer antibiotic with known efficacy.
Purpose:
- To review the established and emerging roles of adriamycin in bladder cancer treatment.
- To highlight its application in both superficial and advanced stages of the disease.
Summary:
- Adriamycin is utilized intravesically for superficial bladder cancer to prevent tumor cell implantation post-transurethral resection, reduce recurrence rates, and treat residual tumors.
- Cisplatin-based combination chemotherapy regimens incorporating adriamycin are effective for managing locally and systemically advanced bladder cancer.
Impact:
- Adriamycin offers a versatile therapeutic option for various bladder cancer presentations.
- Its use contributes to improved outcomes in bladder cancer management, from early-stage disease to advanced systemic disease.